The combined use of amantadine and 1-dopa/carbidopa in the treatment of chronic brain injury

Brain Injury

Volumn 11, Issue 6, 1997, Pages 455-460

  Kraus, Marilyn F ^a   Maki, Pauline ^b  

^a W Psychiatric Institute and Clinic   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; CARBIDOPA; LEVODOPA;

ADULT; ARTICLE; ATTENTION; BRAIN INJURY; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; FRONTAL LOBE; HANDWRITING; HUMAN; IMPULSIVENESS; MOTIVATION; PERSEVERATION; PROBLEM SOLVING; SPEECH; BEHAVIOR; CHRONIC DISEASE; COGNITION; DRUG COMBINATION; DRUG EFFECT; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL ASPECT;

AMANTADINE; BEHAVIOR; BRAIN INJURIES; CARBIDOPA; CHRONIC DISEASE; COGNITION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 0030612255     PISSN: 02699052     EISSN: None     Source Type: Journal    
DOI: 10.1080/026990597123430     Document Type: Article

References (39)

1. INTERAGENCY HEAD INJURY TASK FORCE: Report, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD February 1989.
2. LEVIN, H., WILLIAMS, D., EISENBERG, H., et al.: Serial magnetic resonance imaging and neurobehavioural findings after mild to moderate closed head injury. Journal of Neurology, Neurosurgery and Psychiatry, 55: 255-262, 1992.
3. VECHT, C. J., VAN WOEKOM, T. C. A. M., TEELKEN, A. W. et al.: Homovanillic acid and 5-hydroxy indoleacetic acid cerebrospinal fluid levels. Archives of Neurology, 32: 792-797, 1975.
4. PEARLSON, G. D. and ROBINSON, R. G.: Suction lesions of the frontal cerebral cortex in the rat induced asymmetrical behavioral and catechominergic responses. Brain Research, 218: 233-242, 1981.
5. VAN WOERKOM, T. C., TEELKEN, A. W. MINDERHOUD, J. M., et al.: Difference in neurotransmitter metabolism in frontotemporal love contusion and diffuse cerebral contusion. Lancet, 1: 812-813, 1977.
6. LEVIN, H. and KRAUS, M. F.: The frontal lobes and traumatic brain injury. Journal of Neuropsychiatry and Clinical Neuroscience, 6: 443-454, 1994.
7. BROWN, R. M., CRANE, A. M. and GOODMAN, P. S.: Regional distribution of monomaines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Research, 168: 133-150, 1979.
8. WOLFE, N., KATZ, D. I., ALBERT, M. L., et al.: Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 53: 915-917, 1990.
9. CEDARBAUM, J. M. and MCDOWELL, F. H.: Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems. In M. D. Yahr and K. J. Bergman (editors) Advances in Neurology (Raven Press, New York), vol. 45, pp. 469-472, 1986.
10. GILMAN, A. G., RALL T. W. and NIES, A. S. (editors) The Pharmacologic Basis of Therapeutics (Pergamon Press, New York) pp. 466-472, 1990.
11. HERRMAN, E. C., GRABLIKS, J., ENGLE, C., et al.: Antiviral activity of L-adamantanamine (amantadine). Proc Soc Exp biol Med, 103: 625, 1960.
12. SCHWAB, R. S., ENGLAND, A. C., POSTKANZER, D. C., et al.: Amantadine in the treatment of Parkinson's disease, JAMA, 208: 1168-1170, 1969.
13. AOKI, F. and SITAR, D.: Clinical pharmacokinetics of amantadine hydrochloride. Clinical Pharmacokinetics, 14: 35-51, 1988.
14. GIANUTSOS, G., STEWART, C. and DUNN, J. P.: Pharmacologic changes in dopaminergic systems induced by long-term administration of amantadine. European Journal of Pharmacology, 110: 357-61, 1985.
15. ALLEN, R. M.: Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clinical Neuropharmacology, 6(suppl. 1): S64-73, 1983.
16. WELLER, M. and KORNHUBER, J.: A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Medical Hypostheses, 38: 329-333, 1992.
17. SCHNEIDEN, H., COX, B.: A comparison between amantadine and bromocriptine using the stereotyped behaviour response test (SBR) in the rat. European Journal of Pharmacology, 39: 133-141, 1976.
18. LAL, S., MERBITZ, C. P. and GRIP, J. C.: Modification of function in head-injured patients with sinemet. Brain Injury, 2: 225-233, 1988.
19. WOLF, A. P. and GLECKMAN, A. D.: L-dopa/carbidopa and brain injury: funcitonal versus statistical change and suggestions for future research designs. Brain Injury, 9: 487-493, 1995.
20. GUALTIERI, T., CHANDLER, M., COONS, T. B. and BROWN, L. T.: Amantadine: a new clinical profile for traumatic brain injury. Clinical europharmacohgy, 12: 258-270, 1989.
21. VAN REEKUM, R. BAYLEY, M., GARNER, S., et al.: N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Injury. 9: 49-53, 1995.
22. ANDERSSON, S., BERSTAD, J. FINSET, A., et al.: Amantadine in cognitive failure in patients with traumatic head injuries. Tidsskr Nor laegeforen, 112: 2070-2072, 1992.
23. NICKELS, J. L., SCHNEIDER, W. N., DOMBOVY, M. L., et al.: Clinical use of amantadine in brain injury rehabilitation. Brain Injury, 8: 709-718, 1994.
24. HORIGUCHI, J., INAMI, Y. and SHODA, T.: Effects of long term amantadine treatment on clinical symptoms and EEG of a patient in a vegetative state. Clinical Neuropharmacology, 13: 84-88, 1990.
25. KRAUS, M. F. and MAKI, P. M.: The effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injured patients: case studies and review (in press).
26. FOLSTEIN, M. F., FOLSTEIN, S. E. and MCHUGH, P.: Mini-mental state: a practical method for grading cognitive state of the patient for the clinician. Journal of Psychiatric Research, 12: 189-198, 1985.
27. ALBERT, M. and COHEN, C.: The test for severe impairment: An instrument of the assessment of patients with severe cognitive dysfunction. Journal of the American Geriatric Society, 40: 449-453, 1992.
28. SUNDERLAND, T., HILL, J. L., MELLOW, A. M., et al.: Clock drawing in Alzheimer's disease: a novel measure of dementia severity. Journal of the American Geriatric Society, 37: 725-729, 1989.
29. BRANDT, J.: The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clinical Neuropsychology, 5: 125-142, 1991.
30. SCHRETLEN, D.: Brief Test of Attention (Author, Baltimore, MD), 1989.
31. BENTON, A. L.: Differential behavioral effects in frontal lobe disease. Neuropsychologia, 6: 53-60, 1968.
32. REITAN, R. M. and WOLFSON, D.: The Halstead-Reitan Neuropsychological Test Battery (Neuropsychology Press, Tuscan), 1985.
33. WECHSLER, D., Wechsler Memory Scale-revised (Psychological Corporation, New York), 1987.
34. FRITH, C. D., FRISTON, K. J., LIDDLE, P. F., et al.: A PET study of word finding. Neuropsychologia, 29: 1137-1148, 1991.
35. PARKS, R. W., LOEWENSTEIN, D. A., DODRILL, K. L., et al.: Cerebral metabolic effects of a verbal fluency test: a PET scan study. Journal of Clinical and Experimental Neuropsychology, 10: 565-575, 1988.
36. REITAN, R. M. and WOLFSON, D.: Category test and trail making test as measures of frontal lobe functions. Clinical Neuropsychology, 9: 50-56, 1995.
37. WARKENTIN, S. and PASSANT, U. Frontal activation of the frontal lobes: regional cerebral blood flow findings in normals and in patient with frontal lobe dementia performing a word fluency test. Dementia, 4: 188-191, 1993.
38. FEENEY, D., GONZALES, A. and LAW, W.: Amphetamine, haloperidol and experience interact to affect rate of recovery after motor cortex injury. Science, 217: 855-857, 1982.
39. FEENEY, D. M. and SUTTON, R. L.: Pharmacotherapy for recovery of function after brain injury. CRC Critical Reviews in Neurobiology, 3: 135-197, 1987.